US Stock MarketDetailed Quotes

ITCI Intra-Cellular Therapies

Watchlist

72.130
-0.990-1.35%

Close Apr 25 16:00 ET

72.130
0.0000.00%

Post 16:20 ET

7.60BMarket Cap-49404P/E (TTM)

Intra-Cellular Therapies Stock Forum

Meltyy

Apr 1 15:47

Biotech Stock Catalyst Watchlist

🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies(ITCI.US)$ Phase 3
$CG Oncology(CGON.US)$ Phase 3
$Hutchmed (China)(HCM.US)$ Phase 3
$Viracta Therapeutics(VIRX.US)$ Phase 3
$GlycoMimetics(GLYC.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$UroGen Pharma Ltd(URGN.US)$ Phase 3
$Lyra Therapeutics(LYRA.US)$ Phase 3
$Citius Pharmaceuticals(CTXR.US)$ Phase 3
$Marinus Pharmaceuticals(MRNS.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3...

Moomoo AI

Mar 27 23:03

Intra-Cellular Therapies is nearing breakeven, contingent on maintaining a 57% annual growth rate. Its lack of debt, unusual for a pharma company, reduces investment risk.

Market Sentiment Around Loss-Making Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Meltyy

Mar 22 10:48

Mental Health Biotech Catalyst Watchlist

$Vanda Pharmaceuticals(VNDA.US)$ PDUFA
$Intra-Cellular Therapies(ITCI.US)$ Phase 3
$Bristol-Myers Squibb(BMY.US)$ PDUFA
$Alzamend Neuro(ALZN.US)$ Phase 2
$Alzamend Neuro(ALZN.US)$ Phase 2a

Meltyy

Feb 22 12:05

Biotech Stock Catalyst Watchlist

🎯 Ph 3 readouts in Q1 2024...
$Pfizer(PFE.US)$ Phase 3
$Palatin Technologies(PTN.US)$ Phase 3
$Annovis Bio(ANVS.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$$Novocure(NVCR.US)$ Phase 3
$ROCHE HOLDING AG(RHHBY.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US)$ Phase 3
$Sellas Life Sciences(SLS.US)$...

Moomoo AI

Feb 14 22:15

The market seems optimistic about Intra-Cellular Therapies, Inc. given its strong revenue growth and share price momentum. It's recommended to take a closer look at this stock.

Intra-Cellular Therapies (NASDAQ:ITCI) Shareholders Have Earned a 39% CAGR Over the Last Five Years

Meltyy

Feb 1 04:38

Ph 3 readouts in Q1 2024...

$Pfizer(PFE.US)$ Phase 3
$Regenxbio(RGNX.US)$ Phase 3
$Annovis Bio(ANVS.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 3
$Vertex Pharmaceuticals(VRTX.US)$ Phase 3
$KalVista Pharmaceuticals(KALV.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$Novocure(NVCR.US)$ Phase 3
$ROCHE HOLDING AG(RHHBY.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$Applied Therapeutics(APLT.US)$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US)$ Phase 3...

Moomoo AI

Jan 24 21:45

Recent insider selling at Intra-Cellular Therapies, especially by Mark Neumann, could negatively impact the stock. Despite high insider ownership, the absence of insider purchases over the past year suggests insiders don't see the shares as a bargain.

34% Of This Intra-Cellular Therapies Insider's Holdings Were Sold

Moomoo AI

Jan 4 10:01

Intra-Cellular Therapies' high P/S ratio may signal investor hope for strong revenue, though analysts show less confidence. Their high valuation could face significant risk due to the disparity between the P/S ratio and revenue predictions.

Unpleasant Surprises Could Be In Store For Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Shares

Moomoo AI

Oct 26, 2023 20:55

The substantial ownership of Intra-Cellular Therapies' shares by insiders hints at alignment with shareholders, but the absence of recent insider buying and significant insider selling in the past year could mar confidence. Analyst forecasts might offer a clearer view on the investment.

23% Of This Intra-Cellular Therapies Insider's Holdings Were Sold

Moomoo AI

Oct 26, 2023 20:44

Despite substantial ownership of Intra-Cellular Therapies' shares by insiders, the lack of recent insider buying and considerable selling could affect confidence. Analyst forecasts may offer a better investment perspective.

23% Of This Intra-Cellular Therapies Insider's Holdings Were Sold

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall